New report on Stem Cell Therapeutics Markets has in Visionshopsters

political and business events to announce changes for Stem Cell Therapeutics, in particular the expected movement of President Barack Obama on federal funding restrictions on stem cell research raise. The U.S. Congress also has a desire to specify forward on stem cell research. The dynamics in both branches of American government, along with the scientific developments and the competition on world markets heralds good market for stem cell research. http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. html With their ability to differentiate and to an ongoing source of cells that make up critical tissues and organs, stem cells have the potential for new regenerative therapies and as new research tools for drug developers to new therapies to test in diseased cells. During

companies have the opportunity to find outside the U.S., President Bush has limited seven-year restrictions on embryonic stem cell research in the U.S., the U.S. market. should initiate changes in U.S. policy in U.S. markets. For market watchers in the pharmaceutical industry is the question of what potential they have and where to take them off the market. Kalorama Information has taken on this issue in the stem cells Therapeutics Markets addressed. Kalorama analyst Alison Sahoo has built models to determine the best, and most likely case scenarios for the therapeutic market for stem cells in the coming years. This report is divided projected revenue and procedure volume for the stem cell technologies for these segments in the areas of disease: Cardiovascular disease < p> lung disease Arthritis incontinence osteoporosis Diabetes <

p> Cancer Orthopedics infertility Alzheimer’s Burns (severe) ;

lupus Parkinson’s disease liver failure Multiple Sclerosis Critical limb ischemia Crohn’s disease sickle cell anemia Multiple myeloma

NH’s lymphoma

leukemia Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of the medical and social literature, government databases and publications. As part of this comprehensive analysis of stem cell research markets, the following companies were profiled: Aastrom Biosciences Advanced Cell Technologies Brainstorm Cell Therapeutics Celegene ES Cell International MEDISTER Neostem ; Opexa Therapeutics Osiris Therapeutics Plureon Regenetech Revivicor < p> Stem Cell Sciences StemLifeLine thermogenesis VetCell Bioscience To know more and this report in order to buy a copy please visit:
http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. html